Oncolytics Biotech® Inc. is focused on the development of oncolytic viruses for use as cancer therapeutics. The Company's lead product, REOLYSIN®, a proprietary formulation of the human reovirus, is in late-stage clinical testing in a range of cancers. REOLYSIN has been utilized in nearly 30 clinical trials including translational, Phase I, Phase II (single arm and randomized) and Phase III studies in a broad range of cancer indications. To date, Oncolytics has been issued more than 370 patents worldwide and has more than 230 pending applications. Issued patent claims pertaining to the reovirus cover: compositions of matter comprising reovirus; pharmaceutical use of reoviruses to treat neoplasia and cellular proliferative diseases and combination therapy with radiation, chemotherapy and/or immune suppressants.
Keywords: REOLYSIN®; anti-PD-1; combination therapy; introduction; melanoma; oncolytic virus; reovirus.